oral kinesin motor protein inhibitor - Amgen, Thousand Oaks, CA

oral kinesin motor protein inhibitor

relative AMG 650 in Ph. I for cancer

from ~600k compounds HTS + opt

J. Med. Chem.

Amgen, Thousand Oaks, CA

Context. “Compound 24” (Amgen) is a kinesin-like protein 18A (KIF18A) inhibitor being developed for a subset of cancers with chromosomally unstable tumor cells. Their first-in-class, oral clinical candidate, AMG…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.